BTBP(SH:600161)2023-04-24 16:00Financial Performance - The company's operating revenue for Q1 2023 reached ¥1,291,975,871.24, representing an increase of 83.30% compared to the same period last year[4]. - Net profit attributable to shareholders was ¥261,909,016.67, marking a significant increase of 109.23% year-on-year[4]. - Basic earnings per share (EPS) stood at ¥0.16, which is an increase of 109.23% year-on-year[4]. - Operating profit for Q1 2023 was ¥427,356,672.03, up 106.7% from ¥206,670,065.85 in the same period last year[18]. - Net profit for Q1 2023 was ¥358,982,561.98, representing a 104.5% increase from ¥175,553,905.62 in Q1 2022[19]. - The net profit after deducting non-recurring gains and losses was ¥253,182,543.90, up 118.19% year-on-year[4]. - The company reported a significant increase in other receivables, which rose to RMB 31,983,884.62 from RMB 28,361,261.82, a growth of approximately 9.25%[13]. Cash Flow - The net cash flow from operating activities was ¥620,695,486.70, reflecting a substantial increase of 199.46% compared to the previous year[4]. - Cash flow from operating activities for Q1 2023 was ¥620,695,486.70, compared to ¥207,272,943.62 in Q1 2022, indicating a growth of 199.5%[21]. - The company reported a net cash inflow from operating activities of ¥1,446,562,862.88 for Q1 2023, compared to ¥883,891,324.30 in Q1 2022[21]. - The net cash flow from investing activities was -¥201,374,271.14 for the first quarter of 2023, compared to -¥266,163,915.06 in the same period last year[22]. - The company generated CNY 130,561,428.59 in net cash flow from investing activities in Q1 2023, a significant improvement from negative CNY 18,833,608.89 in Q1 2022[28]. Assets and Liabilities - Total assets at the end of Q1 2023 amounted to ¥13,512,920,082.80, a growth of 4.42% from the end of the previous year[5]. - The company's total liabilities increased to RMB 1,365,270,017.66, compared to RMB 1,157,348,349.10, indicating a rise of about 17.94%[14]. - Total liabilities as of Q1 2023 amounted to ¥1,797,598,125.04, an increase from ¥1,584,369,943.88 in the previous year[18]. - The company's total current assets increased to ¥2,366,625,651.49 as of March 31, 2023, from ¥2,172,791,737.09 a year earlier, reflecting a growth of approximately 8.9%[24]. - The company's cash and cash equivalents reached RMB 4,135,912,849.98, up from RMB 3,712,890,052.98, indicating an increase of about 11.39%[13]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 61,733[10]. - The largest shareholder, China Biotechnology Co., Ltd., holds 45.64% of the shares, totaling 752,083,740 shares[10]. Research and Development - Research and development expenses for Q1 2023 were ¥9,539,026.33, a decrease of 57.8% from ¥22,631,280.65 in Q1 2022[18]. - The company has not disclosed any new product developments or market expansion strategies in the current report[12]. Other Financial Metrics - The weighted average return on equity (ROE) was 2.93%, an increase of 1.39 percentage points compared to the previous year[4]. - The total cost of operations for Q1 2023 was ¥883,395,917.16, which is 70.7% higher than ¥517,977,148.28 in Q1 2022[18]. - The company's inventory decreased slightly to RMB 2,280,679,350.92 from RMB 2,332,002,006.69, a decline of about 2.21%[14]. - The company's long-term equity investments remained unchanged at RMB 173,924,750.15[14].